We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Pattern of Cancer in Breast Predicts Outcome

By Biotechdaily staff writers
Posted on 02 Jan 2003
In breakthrough research, scientists have found that by using a microarray and gene chips, they can predict from the genetic pattern of a cancerous breast tumor whether it will spread or might be easily cured. More...
The research was reported in the December 19, 2002, issue of The New England Journal of Medicine.

The scientists say the new genetic profiling method appears better able to predict mortality than measures such as stage, tumor size, or whether the cancer has spread to the lymph nodes. In a surprising finding, large tumors often had a good genetic profile, while small tumors often had a bad genetic profile. This discovery suggests that certain deadly tumors have the potential to be life-threatening even when small, and that no matter what size a tumor is, its fate has already been determined.

The study involved 295 breast cancer patients, 52 or younger when their diagnosis was made, who had been given standard treatment for around 11 years. Tissue from their tumors was stored, so doctors knew which tumors had spread to the nodes when the diagnosis was made. In addition, they knew whether the cancer had spread or if the patient had remained free of cancer after her initial treatment. The study showed that only 5.5% of patients whose genetic signature indicated a good outcome died within the next 10 years, compared to 45% of patients with a bad genetic signature.

The current study, led by Dr. Rene Bernards, professor of molecular carcinogenesis at the Netherlands Cancer Institute (Amsterdam), is a follow-up study to an earlier one conducted by Dr. Bernards several years ago. Now, researchers at Harvard Medical School are planning to begin a study of 500 women, using the same method.




Related Links:
Netherlands Cancer Institute

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.